1.Essential thrombocythemia.
Wook Bum PYUN ; Sung Nam KIM ; Soon Nam LEE ; Jin Young BACK ; Ki Sook HONG
Korean Journal of Hematology 1992;27(2):361-368
No abstract available.
Thrombocythemia, Essential*
2.Essential thrombocythemia.
Soo Gyeong KIM ; Se Jun HONG ; Hyun Soo KIM ; Woo Ik JANG ; Young Hak SHIM ; Myeongseo KANG
Korean Journal of Hematology 1992;27(1):141-147
No abstract available.
Thrombocythemia, Essential*
4.Acute Ischemic Stroke Associated With Essential Thrombocythemia and JAK2 Mutation.
Ku Eun LEE ; Hyun Soon JANG ; Eun Hye JEONG ; Hyun Jeung YU ; Sook Young ROH
Journal of the Korean Neurological Association 2014;32(2):129-131
No abstract available.
Cerebral Infarction
;
Stroke*
;
Thrombocythemia, Essential*
5.Management of Polycythemia Vera and Essential Thrombocythemia.
Korean Journal of Medicine 2014;86(1):26-29
No abstract available.
Polycythemia Vera*
;
Polycythemia*
;
Thrombocythemia, Essential*
6.Essential thrombocythemia occurred in mother and daughter.
Jianqing DENG ; Qi HU ; Min LIU ; Hongyu ZHANG ; Yunlyu WANG
Chinese Journal of Hematology 2014;35(9):872-872
7.Simultaneous presentation of JAK2 V617F mutation-related essential thrombocythemia and B-cell chronic lymphocytic leukemia.
Guido D'ANGELO ; Anna Maria HOTZ ; Fabrizio CIAMBELLI ; Sergio PAULI
Blood Research 2014;49(2):134-137
No abstract available.
Leukemia, Lymphocytic, Chronic, B-Cell*
;
Thrombocythemia, Essential*
8.Case of primary thrombocythemia.
Sheng MA ; Zhiqiang LIU ; Yongchen MA
Chinese Acupuncture & Moxibustion 2015;35(12):1266-1266
9.Correlative study between JAK2 mutation and thrombosis in patients with myeloproliferative neoplasm.
Liang XIA ; Kai-Yang DING ; Xiao-Yan CAI ; Wei-Bo ZHU ; Xin LIU ; Hui-Zhi YANG ; Xiang WAN ; Lin-Lin WU ; Qing-Shu ZENG ; Jing-Sheng WU
Chinese Journal of Hematology 2010;31(9):590-593
OBJECTIVETo investigate the frequency and clinical implication of JAK2 mutation in patients with myeloproliferative neoplasm(MPN)and the correlation between the mutation and thrombosis.
METHODSThe clinical and laboratory data of 107 MPN patients was retrospectively analyzed. JAK2 mutation were detected with allele-specific polymerase chain reaction (AS-PCR) and sequencing. The significance of the mutation in disease diagnosis and molecular pathogenesis and the correlation between the mutation and thrombosis was analysed.
RESULTSJAK2 mutation was detected in 71 (66.4%) and thrombosis in 34 (31.8%) of the 107 MPN patients. Thrombosis occurred in 34.8% (16/46) of polycythemia vera (PV), 32.6% (14/43) of essential thrombocythemia (ET), and 22.2% (4/18) of primany myelofibrosis (PMF) patients. The difference among the 3 groups was not significant (χ(2) = 0.96, P > 0.05). The frequency of thrombosis in JAK2(+) MPN patients (82.4%, 28/34) was higher than that in JAK2(-) MPN patients (17.6%, 6/34) (χ(2) = 5.71, P < 0.05). The frequency of thrombosis in MPN patients > 60 years was higher (41.5%, 27/65) than that in patients < 60 years (16.7%, 7/42) (χ(2) = 7.28, P < 0.01).
CONCLUSIONJAK2 V617F mutation occurs in significant percentage of Chinese patients with MPN. Patients with JAK2 mutation and older age are more succeptible to thrombosis. JAK2 mutation screening in patients with unknown thrombosis is helpful to reveal the underlying latent-MPN.
Humans ; Mutation ; Myeloproliferative Disorders ; genetics ; Neoplasms ; Thrombocythemia, Essential ; genetics ; Thrombosis
Result Analysis
Print
Save
E-mail